, HHC: Hereditary hemorrhagic telangiectasia; HIV: Human immunodeficiency virus; INR: International Normalized Ratio; NIH: National Institute of Health; NO: Nitric oxide
, Primary Pulmonary Hypertension, New England Journal of Medicine, vol.336, issue.2, pp.111-118, 1997.
DOI : 10.1056/NEJM199701093360207
, Updated Clinical Classification of Pulmonary Hypertension, Journal of the American College of Cardiology, vol.54, issue.1, pp.43-54, 2009.
DOI : 10.1016/j.jacc.2009.04.012
, Primary Pulmonary Hypertension: A Pathologic Study of the Lung Vessels in 156 Clinically Diagnosed Cases, Circulation, vol.42, issue.6, pp.1163-84, 1970.
DOI : 10.1161/01.CIR.42.6.1163
, Primary Pulmonary Hypertension Report on a WHO meeting, Geneva: WHO, 1973.
, CLINICAL CLASSIFICATION OF PULMONARY HYPERTERNSION, Clinics in Chest Medicine, vol.22, issue.3, pp.385-91, 2001.
DOI : 10.1016/S0272-5231(05)70278-1
, Exonic Deletions/Duplications in Familial Pulmonary Arterial Hypertension, American Journal of Respiratory and Critical Care Medicine, vol.174, issue.5, pp.590-598, 2006.
DOI : 10.1164/rccm.200602-165OC
, BMPR2 gene rearrangements account for a significant proportion of mutations in familial and idiopathic pulmonary arterial hypertension, Human Mutation, vol.27, issue.2, pp.212-215, 2006.
DOI : 10.1002/humu.9398
, A new nonsense mutation of SMAD8 associated with pulmonary arterial hypertension, Journal of Medical Genetics, vol.46, issue.5, pp.331-338, 2009.
DOI : 10.1136/jmg.2008.062703
, Molecular genetic characterization of SMAD signaling molecules in pulmonary arterial hypertension, Human Mutation, vol.88, issue.12, 2011.
DOI : 10.1002/humu.21605
, Whole Exome Sequencing to Identify a Novel Gene (Caveolin-1) Associated With Human Pulmonary Arterial Hypertension, Circulation: Cardiovascular Genetics, vol.5, issue.3, pp.336-379
DOI : 10.1161/CIRCGENETICS.111.961888
, Mutations of the TGF-?? type II receptorBMPR2 in pulmonary arterial hypertension, Human Mutation, vol.315, issue.2, pp.121-153, 2006.
DOI : 10.1002/humu.20285
, Sporadic primary pulmonary hypertension is associated with germline mutations of the gene encoding BMPR-II, a receptor member of the TGF-beta family, Journal of Medical Genetics, vol.37, issue.10, pp.741-746, 2000.
DOI : 10.1136/jmg.37.10.741
, Endoglin germline mutation in a patient with hereditary haemorrhagic telangiectasia and dexfenfluramine associated pulmonary arterial hypertension, Thorax, vol.59, issue.5, pp.446-454, 2004.
DOI : 10.1136/thx.2003.11890
, Clinical and Molecular Genetic Features of Pulmonary Hypertension in Patients with Hereditary Hemorrhagic Telangiectasia, New England Journal of Medicine, vol.345, issue.5, pp.325-359, 2001.
DOI : 10.1056/NEJM200108023450503
, Guidelines for the diagnosis and treatment of pulmonary hypertension, Revista Portuguesa de Cardiologia (English Edition), vol.31, issue.1, pp.1219-63, 2009.
DOI : 10.1016/j.repce.2011.10.006
, Clinical classification of pulmonary hypertension, Journal of the American College of Cardiology, vol.43, issue.12, pp.5-12, 2004.
DOI : 10.1016/j.jacc.2004.02.037
, Pulmonary arterial hypertension associated with fenfluramine exposure: report of 109 cases, European Respiratory Journal, vol.31, issue.2, pp.343-351, 2008.
DOI : 10.1183/09031936.00104807
, Anorexigens and Pulmonary Hypertension in the United States, Chest, vol.117, issue.3, pp.870-874, 2000.
DOI : 10.1378/chest.117.3.870
, Temporal trends and drug exposures in pulmonary hypertension: An American experience, American Heart Journal, vol.152, issue.3, pp.521-527, 2006.
DOI : 10.1016/j.ahj.2006.02.020
, Benfluorex and Unexplained Valvular Heart Disease: A Case-Control Study, PLoS ONE, vol.5, issue.4, p.10128, 2010.
DOI : 10.1371/journal.pone.0010128.t002
URL : https://hal.archives-ouvertes.fr/hal-00678696
, Pulmonary hypertension associated with benfluorex exposure, European Respiratory Journal, vol.40, issue.5, pp.1164-72
DOI : 10.1183/09031936.00188611
URL : https://hal.archives-ouvertes.fr/hal-00932261
, Is methamphetamine use associated with idiopathic pulmonary arterial hypertension? Chest, pp.1657-63, 2006.
, Pulmonary Arterial Hypertension in Patients Treated by Dasatinib, Circulation, vol.125, issue.17, pp.2128-2165
DOI : 10.1161/CIRCULATIONAHA.111.079921
URL : https://hal.archives-ouvertes.fr/inserm-00697146
, Early detection of pulmonary arterial hypertension in systemic sclerosis: A French nationwide prospective multicenter study, Arthritis & Rheumatism, vol.351, issue.12, pp.3792-800, 2005.
DOI : 10.1002/art.21433
, Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach, Annals of the Rheumatic Diseases, vol.62, issue.11, pp.621088-93, 2003.
DOI : 10.1136/ard.62.11.1088
, Prevalence and characteristics of moderate to severe pulmonary hypertension in systemic sclerosis with and without interstitial lung disease, J Rheumatol, vol.34, issue.5, pp.1005-1016, 2007.
, Evaluation of cardiac abnormalities by Doppler echocardiography in a large nationwide multicentric cohort of patients with systemic sclerosis, Annals of the Rheumatic Diseases, vol.67, issue.1, pp.31-37, 2008.
DOI : 10.1136/ard.2006.057760
, Cardiac involvement in systemic sclerosis assessed by tissue-doppler echocardiography during routine care: A controlled study of 100 consecutive patients, Arthritis & Rheumatism, vol.23, issue.6, pp.1803-1812, 2008.
DOI : 10.1002/art.23463
, Membranoproliferative glomerulonephritis and plexogenic pulmonary arteriopathy in a homosexual man with acquired immunodeficiency syndrome, Human Pathology, vol.18, issue.12, pp.1293-1299, 1987.
DOI : 10.1016/S0046-8177(87)80417-3
, HIV-Related Pulmonary Hypertension, Chest, vol.118, issue.4, pp.1133-1174, 2000.
DOI : 10.1378/chest.118.4.1133
, HIV-associated primary pulmonary hypertension. A case control study. Swiss HIV Cohort Study., American Journal of Respiratory and Critical Care Medicine, vol.155, issue.3, pp.990-995, 1997.
DOI : 10.1164/ajrccm.155.3.9117037
, Prevalence of HIV-related Pulmonary Arterial Hypertension in the Current Antiretroviral Therapy Era, American Journal of Respiratory and Critical Care Medicine, vol.177, issue.1, pp.108-121, 2008.
DOI : 10.1164/rccm.200704-541OC
, Pulmonary vascular disorders in portal hypertension, European Respiratory Journal, vol.11, issue.5, pp.1153-66, 1998.
DOI : 10.1183/09031936.98.11051153
, Pulmonary-Hepatic vascular Disorders (PHD), European Respiratory Journal, vol.24, issue.5
DOI : 10.1183/09031936.04.00010904
, Pulmonary hypertension complicating portal hypertension: Prevalence and relation to splanchnic hemodynamics, Gastroenterology, vol.100, issue.2, pp.520-528, 1991.
DOI : 10.1016/0016-5085(91)90225-A
, Portopulmonary hypertension: Results from a 10-year screening algorithm, Hepatology, vol.112, issue.6, pp.1502-1512, 2006.
DOI : 10.1002/hep.21431
, Die angeborene defecte der kammersheidewand des herzen, Z Klin Med, vol.1897, pp.132-133
, The Eisenmenger Syndrome: I, BMJ, vol.2, issue.5098, pp.701-712, 1958.
DOI : 10.1136/bmj.2.5098.701
, Eisenmenger syndrome. Factors relating to deterioration and death, European Heart Journal, vol.19, issue.12, pp.1845-55, 1998.
DOI : 10.1053/euhj.1998.1046
, ATRIAL SEPTAL DEFECT WITH PULMONARY HYPERTENSION, Heart, vol.23, issue.5, pp.587-598, 1961.
DOI : 10.1136/hrt.23.5.587
, The natural history of ventricular septal defects in infancy, The American Journal of Cardiology, vol.16, issue.5, pp.634-53, 1965.
DOI : 10.1016/0002-9149(65)90047-0
, Caracter??sticas cl??nicas dos pacientes com hipertens??o pulmonar em dois centros de refer??ncia em S??o Paulo, Revista da Associa????o M??dica Brasileira, vol.52, issue.3, pp.139-182, 2006.
DOI : 10.1590/S0104-42302006000300012
, The pathology of the arterial pulmonary vasculature in manson's schistosomiasis, Dis Chest, vol.50, issue.1, pp.72-79, 1966.
, Prevalence of pulmonary hypertension in patients with hepatosplenic Mansonic schistosomiasis?prospective study, Hepatogastroenterology, vol.50, issue.54, pp.2028-2058, 2003.
, Cardiopulmonary Manifestations of Hepatosplenic Schistosomiasis, Circulation, vol.119, issue.11, pp.1518-1541, 2009.
DOI : 10.1161/CIRCULATIONAHA.108.803221
, Pulmonary hypertension in sickle cell disease: cardiac catheterization results and survival, Blood, vol.101, issue.4, pp.1257-61, 2003.
DOI : 10.1182/blood-2002-03-0948
, Pulmonary Hypertension as a Risk Factor for Death in Patients with Sickle Cell Disease. NE n g lJM e d2004, pp.886-895
, Pulmonary Hypertension and Right Heart Failure in Patients With ??-Thalassemia Intermedia, Chest, vol.107, issue.1, pp.50-53, 1995.
DOI : 10.1378/chest.107.1.50
, Pulmonary arterial hypertension after splenectomy for hereditary spherocytosis, Cardiovasc J Afr, vol.18, issue.2, pp.84-93, 2007.
, An Extreme Consequence of Splenectomy in Dehydrated Hereditary Stomatocytosis: Gradual Thrombo???embolic Pulmonary Hypertension and Lung???Heart Transplantation, Hemoglobin, vol.128, issue.5, pp.139-186, 2003.
DOI : 10.7326/0003-4819-130-6-199903160-00014
, Microangiopathic Hemolytic Anemia and Thrombocytopenia in Primary Pulmonary Hypertension, New England Journal of Medicine, vol.287, issue.17, pp.869-70, 1972.
DOI : 10.1056/NEJM197210262871710
, A Hemodynamic Study of Pulmonary Hypertension in Sickle Cell Disease, New England Journal of Medicine, vol.365, issue.1, pp.44-53, 2011.
DOI : 10.1056/NEJMoa1005565
URL : https://hal.archives-ouvertes.fr/inserm-00609555
, Pulmonary Veno-Occlusive Disease, Medicine, vol.87, issue.4, pp.220-253, 2008.
DOI : 10.1097/MD.0b013e31818193bb
URL : https://hal.archives-ouvertes.fr/inserm-01436297
, Pulmonary Veno-occlusive Disease and Pulmonary Capillary Hemangiomatosis, The American Journal of Surgical Pathology, vol.30, issue.7, pp.850-857, 2006.
DOI : 10.1097/01.pas.0000209834.69972.e5
URL : https://hal.archives-ouvertes.fr/inserm-00175850
, CT of the Chest in Pulmonary Venoocclusive Disease, American Journal of Roentgenology, vol.183, issue.1, pp.65-70, 2004.
DOI : 10.2214/ajr.183.1.1830065
, High-resolution CT of the chest in four patients with pulmonary capillary hemangiomatosis or pulmonary venoocclusive disease., American Journal of Roentgenology, vol.171, issue.5, pp.1321-1325, 1998.
DOI : 10.2214/ajr.171.5.9798872
, Pulmonary veno-occlusive disease, European Respiratory Journal, vol.33, issue.1, pp.189-200, 2009.
DOI : 10.1183/09031936.00090608
URL : https://hal.archives-ouvertes.fr/inserm-01436297
, Occult alveolar haemorrhage in pulmonary veno-occlusive disease, European Respiratory Journal, vol.27, issue.1, pp.108-121, 2006.
DOI : 10.1183/09031936.06.00054105
, Pulmonary Hypertension Associated with Left-Sided Heart Disease, Clinics in Chest Medicine, vol.28, issue.1, pp.233-274, 2007.
DOI : 10.1016/j.ccm.2006.12.001
, Pulmonary Hypertension Predicts Mortality and Morbidity in Patients with Dilated Cardiomyopathy, Annals of Internal Medicine, vol.116, issue.11, pp.888-95, 1992.
DOI : 10.7326/0003-4819-116-11-888
, Regression of extreme pulmonary hypertension after mitral valve surgery, The American Journal of Cardiology, vol.30, issue.8, pp.820-826, 1972.
DOI : 10.1016/0002-9149(72)90005-7
, Effects of Mitral-Valve Replacement on the Pulmonary Vascular Dynamics of Patients with Pulmonary Hypertension. NE n g lJM e d1965, pp.509-523
, Pulmonary vascular remodeling in pulmonary hypertension due to chronic heart failure, European Journal of Heart Failure, vol.95, issue.23, pp.1011-1017, 2005.
DOI : 10.1016/j.ejheart.2004.10.021
, Secondary Pulmonary Hypertension in Chronic Heart Failure : The Role of the Endothelium in Pathophysiology and Management, Circulation, vol.102, issue.14, pp.1718-1741, 2000.
DOI : 10.1161/01.CIR.102.14.1718
, Pulmonary Hypertension and Cardiac Function in Adult Cystic Fibrosis, Chest, vol.115, issue.5, pp.1321-1329, 1999.
DOI : 10.1378/chest.115.5.1321
, Combined pulmonary fibrosis and emphysema: a distinct underrecognised entity. E u rR e s p i rJ2005, pp.586-93
, Prognostic value of pulmonary artery pressure in chronic obstructive pulmonary disease., Thorax, vol.36, issue.10, pp.752-760, 1981.
DOI : 10.1136/thx.36.10.752
, Pulmonary Hemodynamics in Advanced COPD Candidates for Lung Volume Reduction Surgery or Lung Transplantation, Chest, vol.127, issue.5, pp.1531-1537, 2005.
DOI : 10.1378/chest.127.5.1531
, Severe Pulmonary Hypertension and Chronic Obstructive Pulmonary Disease, American Journal of Respiratory and Critical Care Medicine, vol.172, issue.2, pp.189-94, 2005.
DOI : 10.1164/rccm.200401-006OC
, Incidence and Prevalence of Chronic Thromboembolic Pulmonary Hypertension: From Acute to Chronic Pulmonary Embolism, Proceedings of the American Thoracic Society, vol.3, issue.7, pp.564-571, 2006.
DOI : 10.1513/pats.200605-112LR
, Incidence of Chronic Thromboembolic Pulmonary Hypertension after Pulmonary Embolism, New England Journal of Medicine, vol.350, issue.22, pp.2257-64, 2004.
DOI : 10.1056/NEJMoa032274
, Assessment of Operability in Chronic Thromboembolic Pulmonary Hypertension, Proceedings of the American Thoracic Society, vol.3, issue.7, pp.584-592, 2006.
DOI : 10.1513/pats.200605-106LR
, Chronic thromboembolic pulmonary hypertension, European Respiratory Journal, vol.23, issue.4, pp.637-685, 2004.
DOI : 10.1183/09031936.04.00079704
, Pulmonary endarterectomy: experience and lessons learned in 1,500 cases, The Annals of Thoracic Surgery, vol.76, issue.5, pp.1457-62, 2003.
DOI : 10.1016/S0003-4975(03)00828-2
, Long-term Use of Sildenafil in Inoperable Chronic Thromboembolic Pulmonary Hypertension, Chest, vol.134, issue.2, pp.229-265, 2008.
DOI : 10.1378/chest.07-2681
, Immunosuppressive therapy in lupus- and mixed connective tissue disease???associated pulmonary arterial hypertension: A retrospective analysis of twenty-three cases, Arthritis & Rheumatism, vol.132, issue.2, pp.521-552, 2008.
DOI : 10.1002/art.23303
, Current and Future Management of Chronic Thromboembolic Pulmonary Hypertension: From Diagnosis to Treatment Responses, Proceedings of the American Thoracic Society, vol.3, issue.7, pp.601-608, 2006.
DOI : 10.1513/pats.200605-111LR
, Unexplained Pulmonary Hypertension in Chronic Myeloproliferative Disorders, Chest, vol.120, issue.3, pp.801-809, 2001.
DOI : 10.1378/chest.120.3.801
, Pulmonary Hypertension Associated with Myeloproliferative Disorders: A Retrospective Study of Ten Cases, Respiration, vol.76, issue.3, pp.295-302, 2008.
DOI : 10.1159/000112822
URL : https://hal.archives-ouvertes.fr/hal-00356272
, Pulmonary Hypertension Secondary to Thrombocytosis in a Patient with Myeloid Metaplasia, Chest, vol.103, issue.2, pp.642-646, 1993.
DOI : 10.1378/chest.103.2.642
, Pulmonary hypertension in polycythemia vera, American Journal of Hematology, vol.92, issue.3, pp.242-246, 1994.
DOI : 10.1002/ajh.2830470320
, Pulmonary hypertension after splenectomy: a consequence of loss of the splenic filter or is there something more?, Thorax, vol.60, issue.12, pp.983-987, 2005.
DOI : 10.1136/thx.2005.043216
, Pulmonary Haemodynamics at Rest and during Exercise in Patients with Sarcoidosis, Respiration, vol.46, issue.1, pp.26-32, 1984.
DOI : 10.1159/000194667
, Clinical predictors of pulmonary hypertension in sarcoidosis, European Respiratory Journal, vol.32, issue.2, pp.296-302, 2008.
DOI : 10.1183/09031936.00175907
, Incidence of Pulmonary Hypertension and Its Clinical Relevance in Patients With Sarcoidosis, Chest, vol.129, issue.5, pp.1246-52, 2006.
DOI : 10.1378/chest.129.5.1246
, Pulmonary hypertension associated with sarcoidosis: mechanisms, haemodynamics and prognosis, Thorax, vol.61, issue.1, pp.68-74, 2006.
DOI : 10.1136/thx.2005.042838
, Lung Transplantation for Pulmonary Langerhans?? Cell Histiocytosis: A Multicenter Analysis, Transplantation, vol.81, issue.5, pp.746-50, 2006.
DOI : 10.1097/01.tp.0000200304.64613.af
, Severe Pulmonary Hypertension in Histiocytosis X, American Journal of Respiratory and Critical Care Medicine, vol.161, issue.1, pp.216-239, 2000.
DOI : 10.1164/ajrccm.161.1.9807024
, Advanced Pulmonary Histiocytosis X Is Associated With Severe Pulmonary Hypertension, Chest, vol.111, issue.4, pp.1142-1146, 1997.
DOI : 10.1378/chest.111.4.1142-a
, Pulmonary hypertension in lymphangioleiomyomatosis: characteristics in 20 patients, European Respiratory Journal, vol.40, issue.3, pp.630-670
DOI : 10.1183/09031936.00093111
, Pulmonary Hypertension in Patients With Neurofibromatosis Type I, Medicine, vol.90, issue.3, pp.201-212
DOI : 10.1097/MD.0b013e31821be2b7
, Pulmonary hypertension in type I glycogen storage disease, Pediatric Cardiology, vol.37, issue.1, pp.54-60, 1990.
DOI : 10.1007/BF02239550
, [Pulmonary hypertension due to glycogen storage disease type II (Pompe's disease): a case report], J Cardiol, vol.19, issue.1, pp.323-355, 1989.
, Pulmonary arterial hypertension and type-I glycogen-storage disease: the serotonin hypothesis. E u rR e s p i rJ, pp.59-65, 2002.
, Type I glycogen storage disease with focal nodular hyperplasia of the liver and vasoconstrictive pulmonary hypertension, Pediatrics, vol.65, issue.2, pp.341-344, 1980.
, Echocardiographic assessment of pulmonary hypertension in Gaucher's disease, The Lancet, vol.351, issue.9115, pp.1544-1550, 1998.
DOI : 10.1016/S0140-6736(98)10194-0
, The frequency and type of lung involvement in patients with Gaucher's disease, Lab Invest, vol.58, 1998.
, Cytomegalovirus and autoimmune liver disease., Journal of Clinical Pathology, vol.42, issue.12, pp.1310-1311, 1989.
DOI : 10.1136/jcp.42.12.1310
URL : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC502075/pdf
, High Prevalence of Autoimmune Thyroid Disease in Pulmonary Arterial Hypertension, Chest, vol.122, issue.5, pp.1668-73, 2002.
DOI : 10.1378/chest.122.5.1668
, Surgical treatment of pulmonary artery sarcoma, The Journal of Thoracic and Cardiovascular Surgery, vol.121, issue.1, pp.77-82, 2001.
DOI : 10.1067/mtc.2001.111423
, Primary pulmonary artery sarcoma: A report of six cases, The Annals of Thoracic Surgery, vol.59, issue.6, pp.1487-90, 1995.
DOI : 10.1016/0003-4975(95)00149-F
, Retrospective institutional study of 31 patients treated for pulmonary artery sarcoma, European Journal of Cardio-Thoracic Surgery, vol.43, issue.4, pp.787-93
DOI : 10.1093/ejcts/ezs387
, Pulmonary Hypertension in Patients With End-Stage Renal Disease, Chest, vol.123, issue.5, pp.1577-82, 2003.
DOI : 10.1378/chest.123.5.1577
, Primary Pulmonary Hypertension, Annals of Internal Medicine, vol.107, issue.2, pp.216-239, 1987.
DOI : 10.7326/0003-4819-107-2-216
, Survival in Patients with Primary Pulmonary Hypertension, Annals of Internal Medicine, vol.115, issue.5, pp.343-352, 1991.
DOI : 10.7326/0003-4819-115-5-343
, Treatment of Pulmonary Arterial Hypertension, New England Journal of Medicine, vol.351, issue.14, pp.1425-1461, 2004.
DOI : 10.1056/NEJMra040291
URL : https://hal.archives-ouvertes.fr/hal-01455600
, Pulmonary Arterial Hypertension in France, American Journal of Respiratory and Critical Care Medicine, vol.173, issue.9, pp.1023-1053, 2006.
DOI : 10.1164/rccm.200510-1668OC
, Survival in Patients With Idiopathic, Familial, and Anorexigen-Associated Pulmonary Arterial Hypertension in the Modern Management Era, Circulation, vol.122, issue.2, pp.156-63, 2010.
DOI : 10.1161/CIRCULATIONAHA.109.911818
, Predicting Survival in Pulmonary Arterial Hypertension: Insights From the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL), Circulation, vol.122, issue.2, pp.164-72, 2010.
DOI : 10.1161/CIRCULATIONAHA.109.898122
, BMPR2 germline mutations in pulmonary hypertension associated with fenfluramine derivatives, European Respiratory Journal, vol.20, issue.3, pp.518-523, 2002.
DOI : 10.1183/09031936.02.01762002
, Genetic Association of the Serotonin Transporter in Pulmonary Arterial Hypertension, American Journal of Respiratory and Critical Care Medicine, vol.173, issue.7, pp.793-800, 2006.
DOI : 10.1164/rccm.200509-1365OC
, Familial and sporadic primary pulmonary hypertension is caused by BMPR2 gene mutations resulting in haploinsufficiency of the bone morphogenetic protein t??ype II receptor, The Journal of Heart and Lung Transplantation, vol.20, issue.2, p.149, 2001.
DOI : 10.1016/S1053-2498(01)00259-5
, Mutation, American Journal of Respiratory and Critical Care Medicine, vol.177, issue.12, pp.1377-83, 2008.
DOI : 10.1164/rccm.200712-1807OC
URL : https://hal.archives-ouvertes.fr/inserm-00668454
, Genetic anticipation and abnormal gender ratio at birth in familial primary pulmonary hypertension., American Journal of Respiratory and Critical Care Medicine, vol.152, issue.1, pp.93-97, 1995.
DOI : 10.1164/ajrccm.152.1.7599869
, Familial primary pulmonary hypertension: clinical patterns, Am Rev Respir Dis, vol.129, issue.1, pp.194-201, 1984.
, Familial Primary Pulmonary Hypertension (Gene PPH1) Is Caused by Mutations in the Bone Morphogenetic Protein Receptor???II Gene, The American Journal of Human Genetics, vol.67, issue.3, pp.737-744, 2000.
DOI : 10.1086/303059
, Heterozygous germline mutations in BMPR2, encoding a TGF-beta receptor, cause familial primary pulmonary hypertension. The International PPH Consortium, Nat Genet, vol.26, issue.1, pp.81-85, 2000.
, Genetics and Genomics of Pulmonary Arterial Hypertension, Journal of the American College of Cardiology, vol.54, issue.1, pp.32-42, 2009.
DOI : 10.1016/j.jacc.2009.04.015
, Clinical outcomes of pulmonary arterial hypertension in patients carrying an ACVRL1 (ALK1) mutation, Am J Respir Crit Care Med, issue.8, pp.181851-61, 2010.
, Clinical Implications of Determining BMPR2 Mutation Status in a Large Cohort of Children and Adults With Pulmonary Arterial Hypertension, The Journal of Heart and Lung Transplantation, vol.27, issue.6, pp.668-74, 2008.
DOI : 10.1016/j.healun.2008.02.009
, 5???-Untranslated Region and a Novel Mutation in Pulmonary Hypertension, American Journal of Respiratory and Critical Care Medicine, vol.176, issue.8, pp.819-843, 2007.
DOI : 10.1164/rccm.200701-164OC
, Update in pulmonary hypertension, Am J Respir Crit Care Med, 2008.
, Clinical and Molecular Genetic Features of Pulmonary Hypertension in Patients with Hereditary Hemorrhagic Telangiectasia, New England Journal of Medicine, vol.345, issue.5, pp.325-334, 2001.
DOI : 10.1056/NEJM200108023450503
, Primary pulmonary hypertension in families with hereditary haemorrhagic telangiectasia, European Respiratory Journal, vol.23, issue.3, pp.373-380, 2004.
DOI : 10.1183/09031936.04.00085504
, Molecular and functional analysis identifies ALK-1 as the predominant cause of pulmonary hypertension related to hereditary haemorrhagic telangiectasia, Journal of Medical Genetics, vol.40, issue.12, pp.40865-71, 2003.
DOI : 10.1136/jmg.40.12.865
, Transforming Growth Factor-?? Receptor Mutations and Pulmonary Arterial Hypertension in Childhood, Circulation, vol.111, issue.4, pp.435-476, 2005.
DOI : 10.1161/01.CIR.0000153798.78540.87
, Implications of Mutations of Activin Receptor-Like Kinase 1 Gene (<i>ALK1</i>) in Addition to Bone Morphogenetic Protein Receptor II Gene (<i>BMPR2</i>) in Children With Pulmonary Arterial Hypertension, Circulation Journal, vol.72, issue.1
DOI : 10.1253/circj.72.127
, Clinical features of pulmonary arterial hypertension in young people with an ALK1 mutation and hereditary haemorrhagic telangiectasia, Archives of Disease in Childhood, vol.94, issue.7, pp.506-517, 2009.
DOI : 10.1136/adc.2007.133082
, ??valuation pronostique de biomarqueurs dans l???hypertension art??rielle pulmonaire, Revue des Maladies Respiratoires, vol.21, issue.6, pp.1137-1180, 2004.
DOI : 10.1016/S0761-8425(04)71589-2
, Altered Growth Responses of Pulmonary Artery Smooth Muscle Cells From Patients With Primary Pulmonary Hypertension to Transforming Growth Factor-??1 and Bone Morphogenetic Proteins, Circulation, vol.104, issue.7, pp.790-795, 2001.
DOI : 10.1161/hc3201.094152
, Hyperproliferative apoptosis-resistant endothelial cells in idiopathic pulmonary arterial hypertension, AJP: Lung Cellular and Molecular Physiology, vol.293, issue.3, pp.548-54, 2007.
DOI : 10.1152/ajplung.00428.2006
, Genes and Pulmonary Arterial Hypertension, Respiration, vol.74, issue.2, pp.123-155, 2007.
DOI : 10.1159/000098818
, Absence of influence of gender and BMPR2 mutation type on clinical phenotypes of pulmonary arterial hypertension, Respiratory Research, vol.17, issue.8, p.73, 2010.
DOI : 10.1093/hmg/ddn059
URL : https://hal.archives-ouvertes.fr/inserm-00668454
, Gene expression in BMPR2 mutation carriers with and without evidence of Pulmonary Arterial Hypertension suggests pathways relevant to disease penetrance, BMC Medical Genomics, vol.3, issue.3, p.45, 2008.
DOI : 10.1016/0960-7404(94)90047-7
, Alterations in oestrogen metabolism: implications for higher penetrance of familial pulmonary arterial hypertension in females, European Respiratory Journal, vol.34, issue.5, pp.1093-1102, 2009.
DOI : 10.1183/09031936.00010409
, Treatment of pulmonary arterial hypertension with targeted therapies, Nature Reviews Cardiology, vol.131, issue.9, pp.526-564, 2011.
DOI : 10.1038/nrcardio.2011.104
, Hypoxic Activation of Adventitial Fibroblasts*, Chest, vol.122, issue.6, pp.326-334, 2002.
DOI : 10.1378/chest.122.6_suppl.326S
, Hypoxia-induced pulmonary artery adventitial remodeling and neovascularization: contribution of progenitor cells, AJP: Lung Cellular and Molecular Physiology, vol.286, issue.4, pp.668-78, 2004.
DOI : 10.1152/ajplung.00108.2003
, Three-Dimensional Reconstruction of Pulmonary Arteries in Plexiform Pulmonary Hypertension Using Cell-Specific Markers, The American Journal of Pathology, vol.155, issue.2, pp.411-420, 1999.
DOI : 10.1016/S0002-9440(10)65137-1
, C-Kit???Positive Cells Accumulate in Remodeled Vessels of Idiopathic Pulmonary Arterial Hypertension, American Journal of Respiratory and Critical Care Medicine, vol.184, issue.1, pp.116-139, 2011.
DOI : 10.1164/rccm.201006-0905OC
, Circulating fibrocytes and pulmonary arterial hypertension, European Respiratory Journal, vol.39, issue.1, pp.210-212
DOI : 10.1183/09031936.00039811
, Targeting of c-kit + haematopoietic progenitor cells prevents hypoxic pulmonary hypertension. E u rR e s p i rJ2011, pp.1392-1401
, The Role of Inflammation and Autoimmunity in the Pathophysiology of Pulmonary Arterial Hypertension, Clinical Reviews in Allergy & Immunology, vol.60, issue.1, pp.31-39
DOI : 10.1007/s12016-011-8265-z
, C Chemokine Fractalkine in Pulmonary Arterial Hypertension, American Journal of Respiratory and Critical Care Medicine, vol.165, issue.10, pp.1419-1444, 2002.
DOI : 10.1164/rccm.2106007
, Increased plasma monocyte chemoattractant protein-1 level in idiopathic pulmonary arterial hypertension, Respirology, vol.376, issue.2, pp.158-63, 2006.
DOI : 10.1161/01.CIR.0000097068.49080.A0
, Autoimmunity and pulmonary hypertension: a perspective, European Respiratory Journal, vol.26, issue.6, pp.1110-1118, 2005.
DOI : 10.1183/09031936.05.00045705
, Dendritic cell recruitment in lesions of human and experimental pulmonary hypertension, European Respiratory Journal, vol.29, issue.3, pp.462-470, 2007.
DOI : 10.1183/09031936.00094706
, PATHOBIOLOGY OF PULMONARY HYPERTENSION, Clinics in Chest Medicine, vol.22, issue.3, pp.451-459, 2001.
DOI : 10.1016/S0272-5231(05)70283-5
, Increased plasma serotonin in primary pulmonary hypertension, The American Journal of Medicine, vol.99, issue.3, pp.249-254, 1995.
DOI : 10.1016/S0002-9343(99)80156-9
, Leptin and regulatory T-lymphocytes in idiopathic pulmonary arterial hypertension, European Respiratory Journal, vol.40, issue.4, pp.895-904
DOI : 10.1183/09031936.00159911
URL : https://hal.archives-ouvertes.fr/inserm-00913076
, Pulmonary Lymphoid Neogenesis in Idiopathic Pulmonary Arterial Hypertension, American Journal of Respiratory and Critical Care Medicine, vol.185, issue.3, pp.311-332
DOI : 10.1164/rccm.201105-0927OC
, Cellular and molecular pathobiology of pulmonary arterial hypertension, Journal of the American College of Cardiology, vol.43, issue.12, pp.13-24, 2004.
DOI : 10.1016/j.jacc.2004.02.029
, An Imbalance between the Excretion of Thromboxane and Prostacyclin Metabolites in Pulmonary Hypertension, New England Journal of Medicine, vol.327, issue.2, pp.70-75, 1992.
DOI : 10.1056/NEJM199207093270202
, Phosphodiesterase type 5 inhibitors in pulmonary arterial hypertension, Advances in Therapy, vol.63, issue.9, pp.813-838, 2009.
DOI : 10.1007/s12325-009-0064-z
, Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension, Journal of Clinical Investigation, vol.111, issue.9, pp.1339-1385, 2003.
DOI : 10.1172/JCI17500
, Molecular and cellular basis of pulmonary vascular remodeling in pulmonary hypertension, Progress in Cardiovascular Diseases, vol.45, issue.3, pp.173-202, 2002.
DOI : 10.1053/pcad.2002.130041
, Expression of Endothelin-1 in the Lungs of Patients with Pulmonary Hypertension, New England Journal of Medicine, vol.328, issue.24, pp.1732-1741, 1993.
DOI : 10.1056/NEJM199306173282402
, Attenuated K+ channel gene transcription in primary pulmonary hypertension, The Lancet, vol.351, issue.9104, pp.726-733, 1998.
DOI : 10.1016/S0140-6736(05)78495-6
, Dysfunctional Voltage-Gated K+ Channels in Pulmonary Artery Smooth Muscle Cells of Patients With Primary Pulmonary Hypertension, Circulation, vol.98, issue.14, pp.981400-981406, 1998.
DOI : 10.1161/01.CIR.98.14.1400
, Anorexic Agents Aminorex, Fenfluramine, and Dexfenfluramine Inhibit Potassium Current in Rat Pulmonary Vascular Smooth Muscle and Cause Pulmonary Vasoconstriction, Circulation, vol.94, issue.9, pp.2216-2220, 1996.
DOI : 10.1161/01.CIR.94.9.2216
, 5-hydroxytryptamine and the pulmonary circulation: receptors, transporters and relevance to pulmonary arterial hypertension, British Journal of Pharmacology, vol.98, issue.Suppl., pp.161-169, 2000.
DOI : 10.1038/sj.bjp.0703570
, Serotonin Transporter Inhibitors Protect against Hypoxic Pulmonary Hypertension, American Journal of Respiratory and Critical Care Medicine, vol.168, issue.4, pp.487-93, 2003.
DOI : 10.1164/rccm.200210-1212OC
, Contribution of the 5-HT(1B) receptor to hypoxiainduced pulmonary hypertension: converging evidence using 5-HT ( 1 B ) -r e c e p t o rk n o c k o u tm i c ea n dt h e5 -H T ( 1 B / 1 D ) -r e c e p t o r antagonist GR127935, Circ Res, issue.12, pp.891231-891240, 2001.
, Inhibition of RhoA/Rho kinase pathway is involved in the beneficial effect of sildenafil on pulmonary hypertension, British Journal of Pharmacology, vol.104, issue.Part 2, pp.1010-1018, 2005.
DOI : 10.1038/sj.bjp.0706408
, Inhaled Rho Kinase Inhibitors Are Potent and Selective Vasodilators in Rat Pulmonary Hypertension, American Journal of Respiratory and Critical Care Medicine, vol.171, issue.5, pp.494-503, 2005.
DOI : 10.1164/rccm.200405-637OC
, RhoA and Rho Kinase Activation in Human Pulmonary Hypertension, American Journal of Respiratory and Critical Care Medicine, vol.179, issue.12, pp.1151-1159, 2009.
DOI : 10.1164/rccm.200805-691OC
, HIF-1 and mechanisms of hypoxia sensing, Current Opinion in Cell Biology, vol.13, issue.2, pp.167-71, 2001.
DOI : 10.1016/S0955-0674(00)00194-0
, Involvement of Hypoxia-Inducible Factor 1 in Pulmonary Pathophysiology, Chest, vol.128, issue.6, pp.592-594, 2005.
DOI : 10.1378/chest.128.6_suppl.592S
, Expression of angiogenesis-related molecules in plexiform lesions in severe pulmonary hypertension: evidence for a process of disordered angiogenesis, The Journal of Pathology, vol.88, issue.3, pp.367-74, 2001.
DOI : 10.1002/path.953
, Channels, High Altitude Medicine & Biology, vol.6, issue.2, pp.133-179, 2005.
DOI : 10.1089/ham.2005.6.133
URL : https://hal.archives-ouvertes.fr/hal-00562772
, Pathogenesis and evolution of plexiform lesions in pulmonary hypertension associated with scleroderma and human immunodeficiency virus infection, Human Pathology, vol.28, issue.4, pp.434-476, 1997.
DOI : 10.1016/S0046-8177(97)90032-0
, Pathologic assessment of vasculopathies in pulmonary hypertension, Journal of the American College of Cardiology, vol.43, issue.12, pp.25-32, 2004.
DOI : 10.1016/j.jacc.2004.02.033
, Primary Pulmonary Hypertension: A Histopathologic Study of 80 Cases, Mayo Clinic Proceedings, vol.60, issue.1, pp.16-25, 1985.
DOI : 10.1016/S0025-6196(12)65277-X
, The Pathology of Hypertensive Pulmonary Vascular Disease: A Description of Six Grades of Structural Changes in the Pulmonary Arteries with Special Reference to Congenital Cardiac Septal Defects, Circulation, vol.18, issue.4, pp.533-580, 1958.
DOI : 10.1161/01.CIR.18.4.533
, Inflammation in pulmonary arterial hypertension. E u rR e s p i rJ2003, pp.358-63
, Chemokine RANTES in Severe Pulmonary Arterial Hypertension, American Journal of Respiratory and Critical Care Medicine, vol.165, issue.4, pp.534-543, 2002.
DOI : 10.1164/ajrccm.165.4.2012112
, Fibrous remodeling of the pulmonary venous system in pulmonary arterial hypertension associated with connective tissue diseases, Human Pathology, vol.38, issue.6, pp.893-902, 2007.
DOI : 10.1016/j.humpath.2006.11.022
, Pulmonary arterial hypertension in limited cutaneous systemic sclerosis: a distinctive vasculopathy. E u rR e s p i rJ, pp.371-380, 2009.
, Occult pulmonary haemorrhage in leukaemia., BMJ, vol.2, issue.5964, pp.166-174, 1975.
DOI : 10.1136/bmj.2.5964.166
, Pulmonary capillary hemangiomatosis, Human Pathology, vol.17, issue.11, pp.1144-50, 1986.
DOI : 10.1016/S0046-8177(86)80420-8
, Pulmonary Veno-occlusive Disease Caused by an Inherited Mutation in Bone Morphogenetic Protein Receptor II, American Journal of Respiratory and Critical Care Medicine, vol.167, issue.6, pp.889-94, 2003.
DOI : 10.1164/rccm.200208-861OC
, Diagnosis and differential assessment of pulmonary arterial hypertension, Journal of the American College of Cardiology, vol.43, issue.12, pp.40-47, 2004.
DOI : 10.1016/j.jacc.2004.02.032
, Pulmonary Veno-Occlusive Disease Associated with Severe Reduction of Single-Breath Carbon Monoxide Diffusing Capacity, Respiration, vol.53, issue.4, pp.262-268, 1988.
DOI : 10.1159/000195438
, Exercise Testing to Estimate Survival in Pulmonary Hypertension, Medicine & Science in Sports & Exercise, vol.40, issue.10, pp.1725-1757, 2008.
DOI : 10.1249/MSS.0b013e31817c92c0
, Assessment of Survival in Patients With Primary Pulmonary Hypertension: Importance of Cardiopulmonary Exercise Testing, Circulation, vol.106, issue.3, pp.319-343, 2002.
DOI : 10.1161/01.CIR.0000022687.18568.2A
, Clinical Correlates and Reference Intervals for Pulmonary Artery Systolic Pressure Among Echocardiographically Normal Subjects, Circulation, vol.104, issue.23, pp.2797-802, 2001.
DOI : 10.1161/hc4801.100076
, Ventilation-Perfusion Scintigraphy Is More Sensitive than Multidetector CTPA in Detecting Chronic Thromboembolic Pulmonary Disease as a Treatable Cause of Pulmonary Hypertension, JN u c lM e d2007, pp.680-684
DOI : 10.2967/jnumed.106.039438
, Diagnostic performance of state-of-the-art imaging techniques for morphological assessment of vascular abnormalities in patients with chronic thromboembolic pulmonary hypertension (CTEPH), European Radiology, vol.35, issue.3, pp.607-623
DOI : 10.1007/s00330-011-2290-4
, Interventricular Mechanical Asynchrony in Pulmonary Arterial Hypertension, Journal of the American College of Cardiology, vol.51, issue.7, pp.51750-51757, 2008.
DOI : 10.1016/j.jacc.2007.10.041
, R i g h tv e n t r i c u l a rf u n c t i o ni nc a r d i o v a s c u l a r disease, part I: Anatomy, physiology, aging, and functional assessment of the right ventricle, Circulation, issue.11, pp.1171436-1171484, 2008.
, Guidelines for the diagnosis and treatment of pulmonary hypertension, ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT), pp.302493-537, 2009.
DOI : 10.1016/j.repce.2011.10.006
, Prognostic value of right ventricular mass, volume, and function in idiopathic pulmonary arterial hypertension, European Heart Journal, vol.28, issue.10, pp.1250-1257, 2007.
DOI : 10.1093/eurheartj/ehl477
, Complications of Right Heart Catheterization Procedures in Patients With Pulmonary Hypertension in Experienced Centers, Journal of the American College of Cardiology, vol.48, issue.12, pp.482546-52, 2006.
DOI : 10.1016/j.jacc.2006.07.061
, The REVEAL Registry Risk Score Calculator in Patients Newly Diagnosed With Pulmonary Arterial Hypertension, Chest, vol.141, issue.2, pp.354-62
DOI : 10.1378/chest.11-0676
, Primary pulmonary hypertension: Current therapy, Progress in Cardiovascular Diseases, vol.45, issue.2, pp.115-143, 2002.
DOI : 10.1053/pcad.2002.128449
, Severe Pulmonary Hypertension during Pregnancy, Anesthesiology, vol.102, issue.6, pp.1133-1140, 2005.
DOI : 10.1097/00000542-200506000-00012
, Noncardiothoracic nonobstetric surgery in mild-to-moderate pulmonary hypertension, European Respiratory Journal, vol.35, issue.6, pp.1294-302, 2010.
DOI : 10.1183/09031936.00113009
, Heart rate responses during the 6-minute walk test in pulmonary arterial hypertension, European Respiratory Journal, vol.27, issue.1, pp.114-134, 2006.
DOI : 10.1183/09031936.06.00042705
, Long-term intravenous epoprostenol infusion in primary pulmonary hypertension, Journal of the American College of Cardiology, vol.40, issue.4, pp.780-788, 2002.
DOI : 10.1016/S0735-1097(02)02012-0
, Primary pulmonary hypertension: natural history and the importance of thrombosis, Circulation, vol.70, issue.4, pp.580-587, 1984.
DOI : 10.1161/01.CIR.70.4.580
, The effect of high doses of calciumchannel blockers on survival in primary pulmonary hypertension. NE n g lJM e d1992, pp.76-81
, The Short-term Effects of Digoxin in Patients With Right Ventricular Dysfunction From Pulmonary Hypertension, Chest, vol.114, issue.3, pp.787-92, 1998.
DOI : 10.1378/chest.114.3.787
, Long-Term Response to Calcium Channel Blockers in Idiopathic Pulmonary Arterial Hypertension, Circulation, vol.111, issue.23, pp.3105-3116, 2005.
DOI : 10.1161/CIRCULATIONAHA.104.488486
, An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation, Nature, vol.46, issue.5579, pp.663-668, 1976.
DOI : 10.1016/0090-6980(73)90020-8
, Treatment of Primary Pulmonary Hypertension with Continuous Intravenous Prostacyclin (Epoprostenol), Annals of Internal Medicine, vol.112, issue.7, pp.485-91, 1990.
DOI : 10.7326/0003-4819-112-7-485
, Treatment of pulmonary arterial hypertension with targeted therapies, Nature Reviews Cardiology, vol.131, issue.9, pp.526-564, 2011.
DOI : 10.1038/nrcardio.2011.104
, LONG-TERM TREATMENT OF PRIMARY PULMONARY HYPERTENSION WITH CONTINUOUS INTRAVENOUS EPOPROSTENOL (PROSTACYCLIN), The Lancet, vol.323, issue.8385, pp.1046-1053, 1984.
DOI : 10.1016/S0140-6736(84)91452-1
, A Survey of Diagnostic Practices and the Use of Epoprostenol In Patients With Primary Pulmonary Hypertension, Chest, vol.114, issue.5, pp.1269-75, 1998.
DOI : 10.1378/chest.114.5.1269
, A Comparison of Continuous Intravenous Epoprostenol (Prostacyclin) with Conventional Therapy for Primary Pulmonary Hypertension, New England Journal of Medicine, vol.334, issue.5, pp.296-302, 1996.
DOI : 10.1056/NEJM199602013340504
, Continuous Intravenous Epoprostenol for Pulmonary Hypertension Due to the Scleroderma Spectrum of Disease, Annals of Internal Medicine, vol.132, issue.6, pp.425-459, 2000.
DOI : 10.7326/0003-4819-132-6-200003210-00002
, Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin, AnnInternMed1994, vol.121, issue.6, pp.409-424
, Survival in Primary Pulmonary Hypertension: The Impact of Epoprostenol Therapy, Circulation, vol.106, issue.12, pp.1477-82, 2002.
DOI : 10.1161/01.CIR.0000029100.82385.58
, Long-Term Prostacyclin for Pulmonary Hypertension With Associated Congenital Heart Defects, Circulation, vol.99, issue.14, pp.1858-65, 1999.
DOI : 10.1161/01.CIR.99.14.1858
, Prognostic Factors for Survival in Human Immunodeficiency Virus???associated Pulmonary Arterial Hypertension, American Journal of Respiratory and Critical Care Medicine, vol.167, issue.10
DOI : 10.1164/rccm.200204-330OC
, Intravenous Epoprostenol in Inoperable Chronic Thromboembolic Pulmonary Hypertension, The Journal of Heart and Lung Transplantation, vol.26, issue.4, pp.357-62, 2007.
DOI : 10.1016/j.healun.2006.12.014
, Reduction in Pulmonary Vascular Resistance with Long-Term Epoprostenol (Prostacyclin) Therapy in Primary Pulmonary Hypertension, New England Journal of Medicine, vol.338, issue.5, pp.273-280, 1998.
DOI : 10.1056/NEJM199801293380501
, Primary Pulmonary Hypertension: Improved Long-Term Effects and Survival With Continuous Intravenous Epoprostenol Infusion, Journal of the American College of Cardiology, vol.30, issue.2, pp.343-352, 1997.
DOI : 10.1016/S0735-1097(97)00187-3
, Pharmacokinetics and Steady-State Bioequivalence of Treprostinil Sodium (Remodulin??) Administered by the Intravenous and Subcutaneous Route to Normal Volunteers, Journal of Cardiovascular Pharmacology, vol.44, issue.2, pp.209-223, 2004.
DOI : 10.1097/00005344-200408000-00010
, Continuous Subcutaneous Infusion of Treprostinil, a Prostacyclin Analogue, in Patients with Pulmonary Arterial Hypertension, American Journal of Respiratory and Critical Care Medicine, vol.165, issue.6, pp.800-804, 2002.
DOI : 10.1164/ajrccm.165.6.2106079
, Addition of Inhaled Treprostinil to Oral Therapy for Pulmonary Arterial Hypertension, Journal of the American College of Cardiology, vol.55, issue.18, pp.551915-551937, 2010.
DOI : 10.1016/j.jacc.2010.01.027
, Inhaled Iloprost for Severe Pulmonary Hypertension, New England Journal of Medicine, vol.347, issue.5, pp.322-331, 2002.
DOI : 10.1056/NEJMoa020204
, Long-Term Treatment of Primary Pulmonary Hypertension with Aerosolized Iloprost, a Prostacyclin Analogue, New England Journal of Medicine, vol.342, issue.25, pp.1866-70, 2000.
DOI : 10.1056/NEJM200006223422503
, Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebocontrolled study, The Lancet, vol.358, issue.9288, pp.1119-1142, 2001.
DOI : 10.1016/S0140-6736(01)06250-X
, Bosentan Therapy for Pulmonary Arterial Hypertension, New England Journal of Medicine, vol.346, issue.12, pp.896-903, 2002.
DOI : 10.1056/NEJMoa012212
, Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2, European Respiratory Journal, vol.24, issue.3, pp.353-362, 2004.
DOI : 10.1183/09031936.04.00028404
, Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial, The Lancet, vol.371, issue.9630, pp.3712093-100, 2008.
DOI : 10.1016/S0140-6736(08)60919-8
, Effects of the Dual Endothelin Receptor Antagonist Bosentan in Patients With Pulmonary Arterial Hypertension, Chest, vol.124, issue.1, pp.247-54, 2003.
DOI : 10.1378/chest.124.1.247
, Survival with first-line bosentan in patients with primary pulmonary hypertension, European Respiratory Journal, vol.25, issue.2, pp.244-253, 2005.
DOI : 10.1183/09031936.05.00054804
, Survival in patients with class III idiopathic pulmonary arterial hypertension treated with first line oral bosentan compared with an historical cohort of patients started on intravenous epoprostenol, Thorax, vol.60, issue.12, pp.1025-1055, 2005.
DOI : 10.1136/thx.2005.040618
, Ambrisentan for the Treatment of Pulmonary Arterial Hypertension: Results of the Ambrisentan in Pulmonary Arterial Hypertension, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy (ARIES) Study 1 and 2, Circulation, vol.117, issue.23, pp.1173010-1173019, 2008.
DOI : 10.1161/CIRCULATIONAHA.107.742510
, Long-Term Pulmonary Hemodynamic Effects of Ambrisentan in Pulmonary Arterial Hypertension, The American Journal of Cardiology, vol.108, issue.2, pp.302-309, 2011.
DOI : 10.1016/j.amjcard.2011.03.037
, Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial, The Lancet, vol.360, issue.9337, pp.895-900, 2002.
DOI : 10.1016/S0140-6736(02)11024-5
, Chronic Sildenafil Treatment Inhibits Monocrotaline-induced Pulmonary Hypertension in Rats, American Journal of Respiratory and Critical Care Medicine, vol.169, issue.1, pp.39-45, 2004.
DOI : 10.1164/rccm.200302-282OC
, Sildenafil Citrate Therapy for Pulmonary Arterial Hypertension, New England Journal of Medicine, vol.353, issue.20, pp.2148-57, 2005.
DOI : 10.1056/NEJMoa050010
, Tadalafil Therapy for Pulmonary Arterial Hypertension, Circulation, vol.119, issue.22, pp.2894-903, 2009.
DOI : 10.1161/CIRCULATIONAHA.108.839274
, Tadalafil monotherapy and as add-on to background bosentan in patients with pulmonary arterial hypertension, The Journal of Heart and Lung Transplantation, vol.30, issue.6, pp.632-675, 2011.
DOI : 10.1016/j.healun.2010.11.009
, Addition of Sildenafil to Long-Term Intravenous Epoprostenol Therapy in Patients with Pulmonary Arterial Hypertension, Annals of Internal Medicine, vol.149, issue.8, pp.521-551, 2008.
DOI : 10.7326/0003-4819-149-8-200810210-00004
, Randomized Study of Adding Inhaled Iloprost to Existing Bosentan in Pulmonary Arterial Hypertension, American Journal of Respiratory and Critical Care Medicine, vol.174, issue.11, pp.1257-63, 2006.
DOI : 10.1164/rccm.200603-358OC
, Bosentan treatment in patients with primary pulmonary hypertension receiving nonparenteral prostanoids, European Respiratory Journal, vol.22, issue.2, pp.330-334
DOI : 10.1183/09031936.03.00008003
, Oral sildenafil as long-term adjunct therapy to inhaled iloprost in severe pulmonary arterial hypertension, Journal of the American College of Cardiology, vol.42, issue.1, pp.158-64, 2003.
DOI : 10.1016/S0735-1097(03)00555-2
, Efficacy and Safety of Sildenafil Added to Treprostinil in Pulmonary Hypertension, The American Journal of Cardiology, vol.96, issue.9, pp.1334-1340, 2005.
DOI : 10.1016/j.amjcard.2005.06.083
, Combination therapy with bosentan and sildenafil in idiopathic pulmonary arterial hypertension, European Respiratory Journal, vol.24, issue.6, pp.1007-1017, 2004.
DOI : 10.1183/09031936.04.00051104
, Addition of sildenafil to bosentan monotherapy in pulmonary arterial hypertension, European Respiratory Journal, vol.29, issue.3, pp.469-75, 2007.
DOI : 10.1183/09031936.00081706
, Effect of Macitentan on Morbidity and Mortality in Pulmonary Arterial Hypertension (PAH): Results From the SERAPHIN Trial, Chest, vol.142, issue.4, pp.1026-1026
DOI : 10.1378/chest.1456207
, Pharmacology of Macitentan, an Orally Active Tissue-Targeting Dual Endothelin Receptor Antagonist, Journal of Pharmacology and Experimental Therapeutics, vol.327, issue.3, pp.736-781, 2008.
DOI : 10.1124/jpet.108.142976
, Macitentan: entry-into-humans study with a new endothelin receptor antagonist, European Journal of Clinical Pharmacology, vol.29, issue.10, pp.977-84, 2011.
DOI : 10.1007/s00228-011-1043-2
, Vardenafil in Pulmonary Arterial Hypertension, American Journal of Respiratory and Critical Care Medicine, vol.183, issue.12, pp.1723-1732, 2011.
DOI : 10.1164/rccm.201101-0093OC
, Soluble guanylate cyclase stimulation: an emerging option in pulmonary hypertension therapy, European Respiratory Review, vol.18, issue.111, pp.35-41, 2009.
DOI : 10.1183/09059180.00011112
, First acute haemodynamic study of soluble guanylate cyclase stimulator riociguat in pulmonary hypertension, European Respiratory Journal, vol.33, issue.4, pp.785-92, 2009.
DOI : 10.1183/09031936.00039808
, Riociguat for chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: a phase II study, European Respiratory Journal, vol.36, issue.4, pp.792-801, 2010.
DOI : 10.1183/09031936.00182909
, Riociguat for the treatment of pulmonary hypertension, Expert Opinion on Investigational Drugs, vol.181, issue.1, pp.567-76
DOI : 10.1183/09031936.00182909
, Left ventricular systolic dysfunction associated with pulmonary hypertension riociguat trial (LEPHT): rationale and design, European Journal of Heart Failure, vol.377, issue.8
DOI : 10.1093/eurjhf/hfs071
, Riociguat for interstitial lung disease and pulmonary hypertension: a pilot trial, European Respiratory Journal, vol.41, issue.4, pp.853-60
DOI : 10.1183/09031936.00213911
, Riociguat for the Treatment of Pulmonary Arterial Hypertension, New England Journal of Medicine, vol.369, issue.4, pp.330-370
DOI : 10.1056/NEJMoa1209655
, Structure???activity studies on diphenylpyrazine derivatives: A novel class of prostacyclin receptor agonists, Bioorganic & Medicinal Chemistry, vol.15, issue.21, pp.6692-704, 2007.
DOI : 10.1016/j.bmc.2007.08.010
, 6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy]-N(methylsulfonyl )acetam ide (NS-304), an orally available and long-acting prostacyclin receptor agonist prodrug, J Pharmacol Exp Ther, vol.5, issue.3223, pp.2-4, 2007.
, A long-acting and highly selective prostacyclin receptor agonist prodrug, 2-{4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}-N(methylsulfonyl )acetam ide (NS-304), ameliorates rat pulmonary hypertension with unique relaxant responses of its active form, on rat pulmonary artery, pp.4-6
, Differential Effects of Selexipag and Prostacyclin Analogs in Rat Pulmonary Artery, Journal of Pharmacology and Experimental Therapeutics, vol.343, issue.3, pp.547-55
DOI : 10.1124/jpet.112.197152
, Selexipag: an oral, selective prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension, European Respiratory Journal, vol.40, issue.4, pp.874-80
DOI : 10.1183/09031936.00137511
, PDGF signaling in pulmonary arterial hypertension, Journal of Clinical Investigation, vol.115, issue.10, pp.2691-2695, 2005.
DOI : 10.1172/JCI26593
, Platelet-derived Growth Factor Expression and Function in Idiopathic Pulmonary Arterial Hypertension, American Journal of Respiratory and Critical Care Medicine, vol.178, issue.1, pp.81-89, 2008.
DOI : 10.1164/rccm.200707-1037OC
, MEDIATORS, CYTOKINES, AND GROWTH FACTORS IN LIVER-LUNG INTERACTIONS, Clinics in Chest Medicine, vol.17, issue.1, pp.151-69, 1996.
DOI : 10.1016/S0272-5231(05)70305-1
, Reversal of experimental pulmonary hypertension by PDGF inhibition, Journal of Clinical Investigation, vol.115, issue.10, pp.2811-2832, 2005.
DOI : 10.1172/JCI24838
, Imatinib in Pulmonary Arterial Hypertension Patients with Inadequate Response to Established Therapy, American Journal of Respiratory and Critical Care Medicine, vol.182, issue.9, pp.1171-1178, 2010.
DOI : 10.1164/rccm.201001-0123OC
, Imatinib Mesylate as Add-on Therapy for Pulmonary Arterial Hypertension: Results of the Randomized IMPRES Study, Circulation, vol.127, issue.10, pp.1128-1166
DOI : 10.1161/CIRCULATIONAHA.112.000765
, Cardiotoxicity of the cancer therapeutic agent imatinib mesylate, Nature Medicine, vol.9, issue.8, pp.908-924, 2006.
DOI : 10.1038/nm1446
, Prognosis of Pulmonary Arterial Hypertension*, Chest, vol.126, issue.1, pp.78-92, 2004.
DOI : 10.1378/chest.126.1_suppl.78S
, Graded balloon dilation atrial septostomy in severe primary pulmonary hypertension, Journal of the American College of Cardiology, vol.32, issue.2, pp.297-304, 1998.
DOI : 10.1016/S0735-1097(98)00238-1
, Atrial septostomy as a bridge to lung transplantation in patients with severe pulmonary hypertension, The American Journal of Cardiology, vol.84, issue.6, pp.682-688, 1999.
DOI : 10.1016/S0002-9149(99)00416-6
, Blade Balloon Atrial Septostomy in Patients With Severe Primary Pulmonary Hypertension, Circulation, vol.91, issue.7, pp.2028-2063, 1995.
DOI : 10.1161/01.CIR.91.7.2028
, Atrial Septostomy in Treatment of End-Stage Right Heart Failure in Patients With Pulmonary Hypertension, Chest, vol.131, issue.4, pp.977-83, 2007.
DOI : 10.1378/chest.06-1227
, The registry of the international society for heart and lung transplantation: eighteenth official report???2001, The Journal of Heart and Lung Transplantation, vol.20, issue.8, pp.805-820, 2001.
DOI : 10.1016/S1053-2498(01)00323-0
, Single Lung Transplantation for Primary Pulmonary Hypertension, Chest, vol.98, issue.5, pp.1107-1122, 1990.
DOI : 10.1378/chest.98.5.1107
, Lung and heart-lung transplant practice patterns in pulmonary hypertension centers, The Journal of Heart and Lung Transplantation, vol.20, issue.12, pp.1297-304, 2001.
DOI : 10.1016/S1053-2498(01)00348-5
, Lung transplantation for pulmonary vascular disease, The Annals of Thoracic Surgery, vol.73, issue.1, pp.209-226, 2002.
DOI : 10.1016/S0003-4975(01)03082-X
, Heart-lung transplantation: successful therapy for patients with pulmonary vascular disease. NE n g lJM e d1982, pp.557-64